{
  "symbol": "GLMD",
  "company_name": "Galmed Pharmaceutica",
  "ir_website": "https://www.galmedpharma.com/investor-relations",
  "structured_data": [
    {
      "section_name": "News Articles",
      "links": [
        {
          "title": "News",
          "url": "https://galmedpharma.investorroom.com/press-releases",
          "content": "[![Galmed Logo](./wd_client_files/logo.png)](https://galmedpharma.com/ \"Home\")\n\n# Press Releases\n\n![](/image/Press+release+header.png)\n\n#### Overview\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nMonth Year \n\nSu  |  Mo  |  Tu  |  We  |  Th  |  Fr  |  Sa   \n---|---|---|---|---|---|---  \n25  |  26  |  27  |  28  |  29  |  30  |  1   \n2  |  3  |  4  |  5  |  6  |  7  |  8   \n9  |  10  |  11  |  12  |  13  |  14  |  15   \n16  |  17  |  18  |  19  |  20  |  21  |  22   \n23  |  24  |  25  |  26  |  27  |  28  |  29   \n30  |  31  |  1  |  2  |  3  |  4  |  5   \n  \nCancel  Go\n\nYear All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 KeywordsSearch\n\n![search button](images/gl_lupa.svg)\n\n[Advanced Search](#)\n\n[ Get Alerts![](images/webdriver/email_alerts.png) ](https://galmedpharma.investorroom.com/email-alerts?type=1)\n\nSearch\n\nSearch Headlines Only\n\nFrom\n\nTo\n\nAsset Types\n\nVideo Audio Photos Documents Events Standard\n\n[Basic Search](#)\n\n  * [![](https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=thumbnail)](https://galmedpharma.investorroom.com/2024-09-25-Galmed-publishes-Results-from-Aramchol-Phase-3-Open-Label-part-in-Hepatology)\n\nSep 25, 2024\n\n[![Download PDF](images/icons/pdf-20px.png) Download PDF](https://galmedpharma.investorroom.com/2024-09-25-Galmed-publishes-Results-from-Aramchol-Phase-3-Open-Label-part-in-Hepatology?asPDF)\n\n[Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology](https://galmedpharma.investorroom.com/2024-09-25-Galmed-publishes-Results-from-Aramchol-Phase-3-Open-Label-part-in-Hepatology)\n\nThe paper re-iterates the significant anti-fibrotic effect of Aramchol 300mg BID in patients with metabolic dysfunction associated steatohepatitis (MASH) Data is confirmed using 3 objective...\n\n    * [ Photos 1 ](https://galmedpharma.investorroom.com/2024-09-25-Galmed-publishes-Results-from-Aramchol-Phase-3-Open-Label-part-in-Hepatology#assets_43_190-3)\n\n  * [![](https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=thumbnail)](https://galmedpharma.investorroom.com/2024-09-19-Galmed-Announces-an-Expansion-of-its-Activities-to-Cancer-and-major-Cardiometabolic-Diseases)\n\nSep 19, 2024\n\n[![Download PDF](images/icons/pdf-20px.png) Download PDF](https://galmedpharma.investorroom.com/2024-09-19-Galmed-Announces-an-Expansion-of-its-Activities-to-Cancer-and-major-Cardiometabolic-Diseases?asPDF)\n\n[Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases](https://galmedpharma.investorroom.com/2024-09-19-Galmed-Announces-an-Expansion-of-its-Activities-to-Cancer-and-major-Cardiometabolic-Diseases)\n\nAramchol is the most clinically advanced, first-in-class, Stearoyl-CoA desaturase1 (SCD1) oral inhibitor, demonstrating in Ph2 and Ph3 (open label part) an excellent safety profile with metabolic...\n\n    * [ Photos 1 ](https://galmedpharma.investorroom.com/2024-09-19-Galmed-Announces-an-Expansion-of-its-Activities-to-Cancer-and-major-Cardiometabolic-Diseases#assets_43_189-3)\n\n  * [![](https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=thumbnail)](https://galmedpharma.investorroom.com/2024-04-04-Galmed-Pharmaceuticals-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31,-2023)\n\nApr 4, 2024\n\n[![Download PDF](images/icons/pdf-20px.png) Download PDF](https://galmedpharma.investorroom.com/2024-04-04-Galmed-Pharmaceuticals-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31,-2023?asPDF)\n\n[Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023](https://galmedpharma.investorroom.com/2024-04-04-Galmed-Pharmaceuticals-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31,-2023)\n\nGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, today announced that it has filed its...\n\n    * [ Photos 1 ](https://galmedpharma.investorroom.com/2024-04-04-Galmed-Pharmaceuticals-Ltd-Files-Annual-Report-on-Form-20-F-for-the-Fiscal-Year-Ended-December-31,-2023#assets_43_188-3)\n\n  * Mar 15, 2024\n\n[![Download PDF](images/icons/pdf-20px.png) Download PDF](https://galmedpharma.investorroom.com/2024-03-15-Galmed-Announces-Grant-of-New-Patent-for-the-Combination-of-Aramchol-with-Resmetirom-MGL-3196,-REZDIFFRA-for-the-Treatment-of-NASH-and-Liver-Fibrosis?asPDF)\n\n[Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis](https://galmedpharma.investorroom.com/2024-03-15-Galmed-Announces-Grant-of-New-Patent-for-the-Combination-of-Aramchol-with-Resmetirom-MGL-3196,-REZDIFFRA-for-the-Treatment-of-NASH-and-Liver-Fibrosis)\n\nGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases announced today the grant of a...\n\n  * [![](https://mma.prnewswire.com/media/1713483/Galmed_Pharmaceuticals_Logo.jpg?p=thumbnail)](https://galmedpharma.investorroom.com/2023-11-20-Galmed-Announces-a-delay-in-the-initiation-of-its-Primary-Sclerosing-Cholangitis-PSC-Phase-2a-Study)\n\nNov 20, 2023\n\n[![Download PDF](images/icons/pdf-20px.png) Download PDF](https://galmedpharma.investorroom.com/2023-11-20-Galmed-Announces-a-delay-in-the-initiation-of-its-Primary-Sclerosing-Cholangitis-PSC-Phase-2a-Study?asPDF)\n\n[Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study](https://galmedpharma.investorroom.com/2023-11-20-Galmed-Announces-a-delay-in-the-initiation-of-its-Primary-Sclerosing-Cholangitis-PSC-Phase-2a-Study)\n\nGalmed Pharmaceuticals Ltd. (Nasdaq: GLMD) (\"Galmed\" or the \"Company\"), a clinical-stage biopharmaceutical company for liver, metabolic and fibrotic diseases, announced today a delay of at least 6...\n\n    * [ Photos 1 ](https://galmedpharma.investorroom.com/2023-11-20-Galmed-Announces-a-delay-in-the-initiation-of-its-Primary-Sclerosing-Cholangitis-PSC-Phase-2a-Study#assets_43_186-3)\n\n\n\n\nLoad More\n\nLoading...\n\n[Get Alerts](https://galmedpharma.investorroom.com/email-alerts)\n\n  * [](#print \"print\")\n  * [ ](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fgalmedpharma.investorroom.com%2Findex.php%3Fs%3D43 \"Facebook Share\")\n  * [ ](https://www.linkedin.com/shareArticle?mini=true&url=https%3A%2F%2Fgalmedpharma.investorroom.com%2Findex.php%3Fs%3D43 \"Linkedin Share\")\n  * [ ](https://twitter.com/share?url=https%3A%2F%2Fgalmedpharma.investorroom.com%2Findex.php%3Fs%3D43 \"Twitter Share\")\n  * [](#email \"email\")\n  * [](https://galmedpharma.investorroom.com/index.php?s=95&rsspage=43 \"rss\")\n\n\n\n[Subscribe](#)\n"
        }
      ]
    }
  ]
}